On the cover: Jim, pictured with his fiancée, Thuy, and their dog, is a cancer survivor as well as a nurse caring for patients.
The enduring power of partnership

It’s been almost four years since Park Nicollet Frauenshuh Cancer Center and HealthPartners Cancer Care Centers joined together to provide our patients with the most comprehensive care available, including new weekend infusion hours, expanded research and extensive clinical trials. We’re inspired daily by our patients to improve care while creating incredible synergy through our combined work. We are excited to share with you the progress we’ve made in our 2017 annual report.

Providing timely and convenient care to our patients and families is a priority for us. With seven locations across the metro area and six locations in Wisconsin, we offer all the services a patient may require, close to home.

From infusion and radiation therapy to genetic counseling and clinical trials, we offer comprehensive, advanced care. One-on-one counseling, nutrition and rehabilitation services are vital to caring for the whole patient.

Regions Hospital joined Frauenshuh Cancer Center in offering weekend appointments for infusion to better accommodate our patients’ busy lives.

We continue to stand by our 48-hour promise, our pledge to seeing a patient within 48 hours of a cancer diagnosis. Our goal is to provide excellent care that can be accessed quickly and conveniently when facing a potentially life-altering diagnosis, such as cancer.

Our care is backed by a commitment to medical education and continued advancement in clinical trials. This work is vital to furthering the science and care of cancer treatment. Our team of researchers is actively involved in a number of research projects, including pioneering research on the effectiveness of medical cannabis and Phase I clinical trials. While new treatment options for cancer are growing rapidly, the funding for clinical trials has decreased. In September 2016, the Regions Hospital Foundation’s Wine Auction raised over one million dollars to expand cancer research within our organization. We’re incredibly thankful to the Foundation and donors for their support.

We have continued to carry forward our long traditions of high-quality patient care, innovative treatments and clinical research that benefit our patients and community. As a result of our high standards, both programs are accredited by American College of Surgeons’ Commission on Cancer and American Society of Clinical Oncology’s Quality Oncology Practice Initiative.

If you have questions about this report or the exceptional care we strive to offer every patient, please contact us.
Cancer care locations

MINNESOTA

1 HealthPartners Riverside Cancer Care Center
2 Lakeview Hospital Cancer Care
3 Park Nicollet Clinic & Specialty Center — Burnsville Infusion Center
4 Park Nicollet Clinic & Specialty Center — Maple Grove Infusion Center
5 Park Nicollet Frauenshuh Cancer Center
6 Regions Hospital Cancer Care Center
7 St. Francis Cancer Center

WISCONSIN

8 Amery Hospital and Clinic
   Cancer Center of Western Wisconsin*
9 Hudson Hospital
   Cancer Center of Western Wisconsin*
10 Osceola Medical Center
   Cancer Center of Western Wisconsin*
11 St. Croix Regional Medical Center
   Cancer Center of Western Wisconsin*
12 Western Wisconsin Health
   Cancer Center of Western Wisconsin*
13 Westfields Hospital
   Cancer Center of Western Wisconsin*

*HealthPartners provides physician services in partnership with Cancer Center of Western Wisconsin
Highlights of 2017

New staff

One of the strengths of our program is talented, dedicated colleagues. In 2017, we were fortunate to have many new people join our team.

MEDICAL ONCOLOGY

Peter Hurley, MD
Hematology
Medical Oncology

Craig Mescher, MD
Hematology
Medical Oncology

Karen Rabenau, MD
Hematology
Medical Oncology

Charles Shideman, MD
Radiation Oncology

Jennifer Deidrick, RN

Angela Gray, RN

Carrie Hansen, RN

Char Johnson, LPN

Mai Kow Lor, RN

Cynthia Olive RN, OCN

Anne Paradis, RN

Julie Thurmes, RN

Amber Voss, RN

INFUSION

Kaitlin Durkin RN, BSN

Melinda Gunderson, RN

Hayley Hecksel, RN

Tiffany Kalahar, RN

Jacqueline Konop, RN, BSN

Angela Martizna, RN

Anne Nelson, RN

Jared Schmitz, RN, BSN, OCN

Jennifer Weeks, RN, BSN

TUMOR REGISTRY

Jennifer Pluff, RHIT

Jane Siekkinen, BS, CTR

Awards and achievements

Many of our team members are active in education, research and advocacy to improve cancer care.

BRIAN RANK, MD – In collaboration with former colleague, Colleen Morton, MD, spoke about systems-based hematology care at the American Society of Hematology Annual Meeting in San Diego, California, December 2016.

ARKADIUSZ DUDEK, MD – Elected to serve on the National Cancer Institute (NCI) Gastrointestinal Steering Committee as an NCORP Community Oncology Representative.

MARK WILKOWSKE, MD – Received the prestigious Earl G. Young Physician of Excellence Award in June 2017. This award was established in 1989 to recognize unwavering dedication, kindness, compassion and professional excellence.

DAN ANDERSON, MD and RICHARD PETERSON, MD – Named as Principal Investigators for Metro Minnesota Community Oncology Research Consortium (MMCORC).

DYLАН ZYLLA, MD – 2016 Association of American Cancer Centers (ACCC) Innovator Award winner for Establishing Personal Pain Goals to Improve Patient Care and Decrease Costs.

ALICE SHAPIRO, PHD, RDN – Awarded the 2017 Distinguished Practice Award for oncology nutrition by the Academy of Nutrition and Dietetics, Oncology Nutrition Practice Group. This award recognizes members’ hard work and dedication to oncology nutrition through research, education and care improvement.

PAM PAWLOSKI, PHARMD – Inducted as a fellow into the American College of Clinical Pharmacy (ACCP). This designation recognizes excellence in the practice and science of clinical pharmacy. To be recognized, inductees must be nominated by another ACCP Fellow.

HealthPartners President’s Award

BALKRISHNA JAHAGIRDAR, MD – Accepted HealthPartners President’s Award in November 2017. Honorees are nominated by their colleagues and selected for going above and beyond for our members, patients, community and each other.

In addition, he has been recognized by a number of organizations for his outstanding commitment to medical care:

- Board of Directors, Regions Hospital Foundation
- Board of Directors and Immediate Past President, Minnesota Society of Clinical Oncology
- Member, American Society of Hematology Practice Partnership Committee
- Member, Alliance for Clinical Trials in Oncology, Experimental Therapeutics Committee
- Site Director, Fellowship Program at Regions Hospital
- Site Director, Internal Medicine Residency, Hematology-Oncology at Regions Hospital
- Reached “lifetime maximum” of three awards for Best Teacher of the Year from University of Minnesota’s Hematology, Oncology and Transplantation (HOT) Fellowship
- Consistently ranked as a Top Doctor (oncologist-hematologist) by:
  - Minnesota Monthly’s Top Doctors for Women
  - Minnesota Monthly’s Top Doctors Mpls. St. Paul Magazine
- Consistently nominated for Clinical Excellence Award by peers at HealthPartners

Minnesota Society of Clinical Oncology

We continue to provide leadership and support to the Minnesota Society of Clinical Oncology. This group works to provide advocacy for patients with cancer and promote standards of excellence for high-quality cancer care:

Secretary/Treasurer: Priya Kumar, MBBS, MS
Immediate Past President: Balkrishna Jahagirdar, MD
Member-at-Large: Michael Haley, DO
Member-at-Large: Melissa Sherman, MD

METRO MINNESOTA NURSING SOCIETY

We’re proud to have several colleagues in leadership roles advocate for their profession, colleagues and patients:

Treasurer: Cindy Jacobson, RN, OCN
Secretary: Adina Peck, ANP, GNP
Board Member: Nancy Anson, RN, OCN
Annual Conference Chair: Adina Peck, ANP, GNP
Director at Large: Mary Holland, BSN, OCN

NEW CREDENTIALS

Team members mastered additional skills received oncology certified nurse credentialing:

Jenny Graves, RN, OCN
Emina Mujcic, RN, OCN

Community awareness and healing

HealthPartners and Park Nicollet oncology programs sponsored the Twins Cancer Awareness Night on Aug. 30, 2017. For each ticket sold in a designated area, $1 was donated to our programs. In addition, a former patient was invited to throw out the first pitch.

Many cancer survivors need emotional support to help them understand and cope with the illness they have overcome. The Creating Hope Together Survivorship Event took place Saturday June 17, 2017 with over 300 people in attendance. Keynote speakers/singers were Jearlyn and Jevetta Steele. Cancer survivors released 100 butterflies, a symbol of change and hope.
Critical to our mission of helping patients with cancer is our engagement in education and research. Teaching and education ensure that our clinicians and staff keep pace with new discoveries in cancer diagnosis and treatment. Research, through participation in clinical trials, ensures our patients have access to new and cutting-edge therapies.

HealthPartners and Park Nicollet participate in the Metro-Minnesota Community Oncology Research Consortium (ccop.net), an affiliation of 20 metro area hospitals. This consortium, sponsored by National Cancer Institute and area hospitals, allows patients in our community to have access to over 100 cancer clinical trials. This program’s administrative center is housed at Park Nicollet. HealthPartners physicians Dan Anderson, MD, and Rich Peterson, MD, are the program’s principal investigator and assistant principal investigator.

We’re also taking a leading role in research. HealthPartners, through Wine Auction funding, and Park Nicollet, through Park Nicollet Oncology Research, provide a variety of clinical trials specifically available at our facilities.

**CURRENT CLINICAL TRIALS**

- **STM-03**: Phase 1 Study of Procaspare Activating Compound-2 (PAC-1) in the Treatment of Advanced Malignancies (Component 2)
- **TTC-352-101**: Phase 2 Study of TTC-352 in Patients with Metastatic Breast Cancer Progressing on Endocrine Therapy
- **ARRAY 818-103**: A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI) + Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
- **VYR-MV1-102**: Phase I Neoadjuvant Intravesical NIS Measles Virus (MV-NIS) in Patients Undergoing Cystectomy for Urothelial Carcinoma but Ineligible for Neoadjuvant Cisplatin-based Chemotherapy
- **A Phase Ib/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors**
- **The PISCES Study**: A Multicenter Phase 2, Open-Label Trial of Intratumoral pL12 Plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma Who are Progressing on Either Pembrolizumab or Nivolumab Treatment
- **Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry**
- **INCBI 24360-202**: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination with INCBO24360 in Subjects with Selected Cancers
- **INI-001**: Prospective Observational Multicenter Study to Evaluate the Performance of Inviva Liquid Biopsy Analysis Compared with Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients with Advanced Non-Small Cell Lung Cancer
- **MK3475-S64**: A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
- **BMS CA209920**: Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated, Advanced or Metastatic RCC
- **WO30070**: Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (anti-pd-l1 antibody) as Monotherapy and in Combination with Platinum-based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma
- **INCB 24360-202**: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination with INCB024360 in Subjects with Selected Cancers
- **SNX-275-0602**: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab with or without Enrinostat in Patients with Advanced Triple Negative Breast Cancer with a Phase 1b Lead in Phase
- **POLARIS A5481082**: Palbociclib in Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-Interventional Study
C31006: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 inhibitor) in Combination with Fulvestrant in Women with ER-Positive/HER2-Negative Advanced Metastatic Breast Cancer that Has Progressed During or After Aromatase Inhibitor Therapy

STARTRK-2: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

SNDX-275-0602: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab with or without Enrinostat in Patients with Advanced Triple Negative Breast Cancer with a Phase 1b Lead in Phase 3 trials.
Oncology symposiums and simulations provide continuing education

In collaboration with the staff at the Cancer Center of Western Wisconsin, Park Nicollet Frauentshuh Cancer Center and HealthPartners Cancer Care Centers provide oncology education symposiums for health care providers twice yearly.

The spring 2017 symposium on lung cancer included these presentations:
- Radon by Marc Katz
- Smoking Cessation by David Klevan, MD
- Role of SBRT in the Treatment of Lung Cancer by Michael Haley, DO
- Lung Cancer Screening by Anne Melzer, MD
- Molecular Evaluation of Newly Diagnosed Lung Cancer by Bal Jahagirdar, MD
- Treatment Update in Lung Cancer Care by Brenda Larson, MD

The fall 2017 symposium focused on Supportive Care for our Patients and You, with these presentations:
- Immuno-oncology – Indications & Management of These Drugs by Stephanie Kroon, PA-C, MPAS
- Ethics & Disagreement Between Patients/Family and Medical Recommendations by Don C. Postema, PhD
- What Really Happens With Genetics Counseling? by Katherine Fuhrmann, MS, Certified Genetics Counselor
- What Is Psychotherapy? by Courtney Brunner, MSW, LICSW, LCSW
- Wellbeing-Resiliency and Self-Help by Cami Smalley, MA, PCC

Training the next generation of oncologists

One of the core missions of our organization is to train the next generation of physicians and scientists to be leaders in the field of oncology. Regions Hospital is proud to host clinical training sites for the University of Minnesota Hematology and Oncology Fellowship Program. For more than 25 years, this training has included direct supervision of patient care, didactic lectures and informal teaching sessions. Each year, more than 50 hours of didactic lectures are provided to University of Minnesota medical students, internal medicine residents, hematology-oncology fellows, primary care and emergency room physicians, oncology nurses and pharmacists.

NCI Awards

National Cancer Institute (NCI) awards physicians who enroll a particular number of patients in clinical trials. In 2017, our providers have been awarded:

Silver Certification of Excellence – Daniel Anderson, MD; Bal Jahagirdar, MD; Rachel Lerner, MD; and Dylan Zylla, MD

Certificate of Appreciation – Kurt Demel, MD; Jeffrry Jaffe, MD; Gary Shapiro, MD; and Amy Spomer, MD
### Oncology team

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Anderson, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Peter Argenta, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Kacy Berquist, MSN, APRN, NP-C</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Linda Carson, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Joel Carter, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Cathleen Chen, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Jennifer Colvin, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Janel Cox, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Kurt Demel, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Arkadiusz Dudek, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Mary Ehresman, FNP, ADCN</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Britt Erickson, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Brad Farrell, PharmD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Lori Fewer, CFNP</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Chitra Ganesan, MBBS</td>
<td></td>
</tr>
<tr>
<td>Monique Giordana, PharmD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Michael Haley, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Robert Haselow, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Keith Heaton, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Kristin Hembre, PA-C</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Jason Hoiness, PharmD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Peter Hurley, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Randy Hurley, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Gretchen Ibele, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Lisa Illig, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Jeffrrey Jaffe, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Balkrishna Jahagirdar, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Kathryn Jelle, PA-C</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Yan Ji, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Stephanie Kroon, PA-C</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Kendra Kubiak, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Priya Kumar, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Brenda Larson, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Rachel Lerner, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Ayse Malcolm, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Sarah Manuels, MPAS, PA-C, MPH</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Steven McCormack, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Mark Menge, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Craig Mescher, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Michael Miovic, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Kathryn Moore, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Sally Mullany, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Gretchen Niemioja, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Jason Oakes, PA-C</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Adina Peck, ANP, GNP</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Richard Peterson, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Karen Rabenau, MD</td>
<td>Park Nicollet</td>
</tr>
<tr>
<td>Brian Rank, MD</td>
<td>HealthPartners</td>
</tr>
<tr>
<td>Anne Reiber, ANP, GNP</td>
<td>HealthPartners</td>
</tr>
</tbody>
</table>

On average, 95.7 percent of patients would recommend our providers.
Screening and prevention

BE PINK AND BREAST CANCER AWARENESS
We continued our Be Pink campaign to encourage women in the Twin Cities to be aware, proactive and empowered with their breast health. This includes promoting screenings and early breast cancer detection. Our mobile mammography unit, Mammo-a-go-go, has increased use during the campaign.

HealthPartners, Regions Hospital and Park Nicollet Jane Brattain Breast Center participated again this year in the Susan G. Komen Race for the Cure on Mother’s Day in 2017. Using our Mammo-a-go-go as a backdrop for our booth space, we had notable event engagement, including people rushing over for our annual charm giveaway.

To kick off breast cancer awareness month in October, we presented Country for a Cause and the Be Pink fundraising breakfast in partnership with the Park Nicollet Foundation. These events benefit the Jane Brattain Breast Center community outreach fund providing mammograms to women in need.

COLORECTAL CANCER SCREENING
As part of Colorectal Cancer Screen Awareness month, a social media campaign and video monitors in our clinics reminded people to schedule a colorectal screening. To reach even more patients throughout the year, we mailed FIT tests to those who haven’t been screened in our primary care clinics. FIT tests are an in-home stool sample kit that can be used as a preliminary screening for those who meet certain qualifications.

On Sept. 10, we sponsored and participated in the Get Your Rear in Gear: Tour de Tush race for colon cancer in Minneapolis. Approximately 1,000 participants stopped by our event tent for giveaways and information, including educational materials on FIT testing.

We continued our partnership with Sage, Minnesota’s cancer screening program for low income residents, to screen dozens of patients in 2017.

LUNG CANCER SCREENING
HealthPartners launched a lung cancer screening program May 20, 2017. The goal of the program is to identify lung cancer at an earlier stage to save lives and decrease the cost of lung cancer treatment. Once a patient meets eligibility requirements, the program begins with a shared decision making and counseling session with the patient’s primary care provider. This is followed by a low-dose CT scan. The program also requires results tracking, follow-up activity and submittal to the American College of Radiology (ACR) registry. Studies have shown that this form of secondary prevention can save lives and potentially reduce health care costs.

Skin cancer screening
Our combined oncology departments, in conjunction with our dermatology departments, hosted a free skin cancer screening event for the community on May 6, 2017. There were 115 participants. Follow-up was recommended for nearly 30 percent of the participants.

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>35%*</td>
<td>MALE</td>
</tr>
<tr>
<td>63%*</td>
<td>FEMALE</td>
</tr>
<tr>
<td>58 YEARS</td>
<td>AVERAGE AGE</td>
</tr>
<tr>
<td>46%</td>
<td>FAMILY HISTORY OF SKIN CANCER</td>
</tr>
<tr>
<td>12%</td>
<td>PERSONAL HISTORY OF SKIN CANCER</td>
</tr>
<tr>
<td>60%</td>
<td>TANNING BED USAGE</td>
</tr>
</tbody>
</table>

*Two percent of people screened didn’t identify their gender
COMMUNITY WELL-BEING INITIATIVES

According to the American Cancer Society, certain cancer deaths can be prevented by living healthier lifestyles and “making healthy choices like not smoking, staying at a healthy weight, eating right, keeping active and getting recommended screening tests.” HealthPartners promotes health and well-being in our communities through a variety of projects and initiatives designed to increase activity, encourage better food and beverage choices and reduce the number of people who use tobacco. With more than 55 primary care clinics across our system, these efforts reach thousands of patients and members each year.

ACCOUNTABILITY MEASURES

These accountability measures indicate the portion of breast and colorectal cancer patients treated according to recognized standards of care by diagnosis year. The results are reported to the National Cancer Data Base (NCDB), a joint program of the American College of Surgeons (ACoS) and the American Cancer Society. NCDB is a nationwide oncology outcomes database for more than 1,500 commission-accredited cancer programs.

<table>
<thead>
<tr>
<th>NCDB SELECT BREAST AND COLORECTAL MEASURES</th>
<th>Estimated Performance Rates</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
<th>National Benchmark*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>90%</td>
</tr>
<tr>
<td>Radiation therapy is administered within one year (365 days) of diagnosis for women under age 70 receiving breast-conserving surgery for breast cancer.</td>
<td>Health Partners</td>
<td>91.2%</td>
<td>95.5%</td>
<td>93.3%</td>
<td>90%**</td>
</tr>
<tr>
<td></td>
<td>Park Nicollet</td>
<td>96.4%</td>
<td>99.2%</td>
<td>98.5%</td>
<td></td>
</tr>
<tr>
<td>Combination chemotherapy is considered or administered within four months (120 days) of diagnosis for women under 70 with AJCC T1c N0 M0, or Stage II or III ER and PR negative breast cancer.</td>
<td>Health Partners</td>
<td>92.3%</td>
<td>100%</td>
<td>100%</td>
<td>90%</td>
</tr>
<tr>
<td></td>
<td>Park Nicollet</td>
<td>100%</td>
<td>100%</td>
<td>93.8%</td>
<td></td>
</tr>
<tr>
<td>Tamoxifen or third generation aromatase inhibitor is considered or administered within one year (365 days) of diagnosis for women with AJCC T1c N0 M0, or Stage II or III ER and/or PR positive breast cancer.</td>
<td>Health Partners</td>
<td>95.6%</td>
<td>97.6%</td>
<td>95.7%</td>
<td>90%</td>
</tr>
<tr>
<td></td>
<td>Park Nicollet</td>
<td>98.2%</td>
<td>98.6%</td>
<td>96.5%</td>
<td></td>
</tr>
<tr>
<td><strong>Colon Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>85%</td>
</tr>
<tr>
<td>Adjuvant chemotherapy is considered or administered within four months (120 days) of diagnosis for patients under the age of 80 with AJCC T1c Stage III (lymph node positive) colon cancer.</td>
<td>Health Partners</td>
<td>100%</td>
<td>100%</td>
<td>83.3%</td>
<td>90%**</td>
</tr>
<tr>
<td></td>
<td>Park Nicollet</td>
<td>100%</td>
<td>100%</td>
<td>90%</td>
<td></td>
</tr>
<tr>
<td>At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.</td>
<td>Health Partners</td>
<td>92.7%</td>
<td>95.7%</td>
<td>90.6%</td>
<td>85%</td>
</tr>
<tr>
<td></td>
<td>Park Nicollet</td>
<td>86.4%</td>
<td>94%</td>
<td>89.1%</td>
<td></td>
</tr>
</tbody>
</table>

*Commission-approved programs **Noted as 2013 benchmark from NCDB.
Oncology registry

Most common cancer sites

The four most common cancers for HealthPartners and Park Nicollet patients in 2016 (excluding skin cancers) were breast, lung, prostate and colorectal. These four sites account for 43 percent and 45 percent of all cases.

In Minnesota, the most common cancers listed in order of occurrence as published in the American Cancer Society’s “Cancer Facts and Figures 2016,” are breast, prostate, lung and colorectal. Table 2 compares by site and percent HealthPartners and Park Nicollet case totals with the estimated number of cases in Minnesota and the U.S.

### TABLE 1:
Four most common sites by AJCC stage at HealthPartners and Park Nicollet

<table>
<thead>
<tr>
<th>Stage</th>
<th>HealthPartners</th>
<th>Park Nicollet</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>177</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>400</td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>207</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>IV</td>
<td>36</td>
<td></td>
</tr>
<tr>
<td>UN-KNOWN</td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

Female Breast Cancer 2016
878 TOTAL CASES

Prostate Cancer 2016
430 TOTAL CASES

### TABLE 2:
Four most common cancers sites

Table 2 compares, by site and percentage, HealthPartners and Park Nicollet case totals with estimated number of cancer cases in Minnesota and the U.S.

![Bar charts comparing cancer cases by stage and site for HealthPartners, Park Nicollet, Minnesota, and the U.S.](chart.png)
**TABLE 3:**
Tumor Registry 2016

HealthPartners and Park Nicollet tumor registries contain a comprehensive profile of all newly diagnosed cancer using standards set by the American College of Surgeons.

*Analytic: cases diagnosed and/or having initial therapy at HealthPartners or Park Nicollet
**Non-analytic: cases having all initial therapy elsewhere, seen at HealthPartners or Park Nicollet for further care and treatment

<table>
<thead>
<tr>
<th></th>
<th>HEALTH PARTNERS</th>
<th>PARK NICOLLET</th>
</tr>
</thead>
<tbody>
<tr>
<td>2015</td>
<td>1,721</td>
<td>2,320</td>
</tr>
<tr>
<td>2016</td>
<td>1,868</td>
<td>2,474</td>
</tr>
</tbody>
</table>

**TABLE 4:**
2016 Cancer Cases Diagnoses by Tumor Site and Gender

<table>
<thead>
<tr>
<th>Tumor Site</th>
<th>HEALTH PARTNERS</th>
<th>PARK NICOLLET</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TOTAL</td>
<td>MALE</td>
</tr>
<tr>
<td>Breast</td>
<td>340</td>
<td>5</td>
</tr>
<tr>
<td>Skin</td>
<td>259</td>
<td>150</td>
</tr>
<tr>
<td>Lung</td>
<td>207</td>
<td>98</td>
</tr>
<tr>
<td>Prostate</td>
<td>129</td>
<td>129</td>
</tr>
<tr>
<td>Colorectal</td>
<td>129</td>
<td>61</td>
</tr>
<tr>
<td>Bladder</td>
<td>55</td>
<td>42</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>77</td>
<td>55</td>
</tr>
<tr>
<td>Uterus</td>
<td>78</td>
<td>0</td>
</tr>
<tr>
<td>Other/Ill-defined</td>
<td>68</td>
<td>33</td>
</tr>
<tr>
<td>Leukemia</td>
<td>49</td>
<td>25</td>
</tr>
<tr>
<td>Kidney</td>
<td>48</td>
<td>28</td>
</tr>
<tr>
<td>Nervous System</td>
<td>70</td>
<td>31</td>
</tr>
<tr>
<td>Pancreas</td>
<td>57</td>
<td>30</td>
</tr>
<tr>
<td>Head &amp; Neck</td>
<td>88</td>
<td>59</td>
</tr>
<tr>
<td>Endocrine</td>
<td>57</td>
<td>22</td>
</tr>
<tr>
<td>Other GI</td>
<td>49</td>
<td>25</td>
</tr>
<tr>
<td>Ovary</td>
<td>19</td>
<td>0</td>
</tr>
<tr>
<td>Unknown Primary</td>
<td>15</td>
<td>5</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>27</td>
<td>13</td>
</tr>
<tr>
<td>Esophagus</td>
<td>24</td>
<td>17</td>
</tr>
<tr>
<td>Anus</td>
<td>8</td>
<td>1</td>
</tr>
<tr>
<td>Testis</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Vulva</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>1,868</strong></td>
<td><strong>836</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Site</th>
<th>HEALTH PARTNERS</th>
<th>PARK NICOLLET</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TOTAL</td>
<td>MALE</td>
</tr>
<tr>
<td>Breast</td>
<td>543</td>
<td>6</td>
</tr>
<tr>
<td>Skin</td>
<td>373</td>
<td>234</td>
</tr>
<tr>
<td>Lung</td>
<td>190</td>
<td>79</td>
</tr>
<tr>
<td>Prostate</td>
<td>301</td>
<td>301</td>
</tr>
<tr>
<td>Colorectal</td>
<td>143</td>
<td>79</td>
</tr>
<tr>
<td>Bladder</td>
<td>87</td>
<td>62</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>100</td>
<td>53</td>
</tr>
<tr>
<td>Uterus</td>
<td>91</td>
<td>0</td>
</tr>
<tr>
<td>Other/Ill-defined</td>
<td>12</td>
<td>8</td>
</tr>
<tr>
<td>Leukemia</td>
<td>87</td>
<td>51</td>
</tr>
<tr>
<td>Kidney</td>
<td>65</td>
<td>38</td>
</tr>
<tr>
<td>Nervous System</td>
<td>55</td>
<td>18</td>
</tr>
<tr>
<td>Pancreas</td>
<td>57</td>
<td>31</td>
</tr>
<tr>
<td>Head &amp; Neck</td>
<td>60</td>
<td>50</td>
</tr>
<tr>
<td>Endocrine</td>
<td>58</td>
<td>11</td>
</tr>
<tr>
<td>Other GI</td>
<td>49</td>
<td>26</td>
</tr>
<tr>
<td>Ovary</td>
<td>23</td>
<td>0</td>
</tr>
<tr>
<td>Unknown Primary</td>
<td>34</td>
<td>16</td>
</tr>
<tr>
<td>Multiple Myeloma</td>
<td>25</td>
<td>12</td>
</tr>
<tr>
<td>Esophagus</td>
<td>14</td>
<td>9</td>
</tr>
<tr>
<td>Anus</td>
<td>9</td>
<td>1</td>
</tr>
<tr>
<td>Testis</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td>Vulva</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>2,474</strong></td>
<td><strong>1,147</strong></td>
</tr>
</tbody>
</table>
Quality performance and improvement

We continuously measure clinician and system performance to improve quality and to assist in quickly incorporating new medical knowledge into our care.

NUTRITION AND CANCER CARE
Good nutrition is vital for people with cancer. In 2017, we targeted improved nutritional care for oncology patients across HealthPartners and Regions Hospital to better support the patient experience. A multi-disciplinary work group led a Quality Assessment Performance Improvement (QAPI) project to collect data and research on the needs of patients, patient outcomes, capacity to provide nutrition care and patient-reported quality of life.

FOCUS ON SAFETY AND QUALITY
Many new drug protocols can effectively treat cancer, but must be monitored closely to avoid severe complications. Bleomycin is a drug that is low use, but high risk. As a team, we identified the best care and optimal process for reviewing all critical test results. For accuracy, we aligned care with the most recent journal articles, incorporated consistent monitoring and added the protocol into the electronic medical record. We also built a beacon protocol to provide optimal care.

LUNG CANCER CARE
In conjunction with the new HealthPartners lung cancer screening program, a lung cancer group was developed to determine best practice and appropriate testing based on risk factors. Medical oncology, pulmonology and interventional radiology review images prior to scheduling a lung biopsy to determine the best method and avoid unnecessary procedures while obtaining enough tissue for molecular profiling. From May to October 2017, approximately 205 lung cancer screenings have been completed, with 48 patients needing further testing.
Cancer committee members 2017

Our cancer committees meet quarterly to review all aspects of our program. This includes information related to cancer conferences, community outreach, research and quality improvement, as well as all the teams involved in cancer care.

HEALTHPARTNERS

Rick Aizpuru, MD
Radiology

Sue Braaten, RHIT, CTR
Cancer Registry

Diana Christensen Johnston, RN, OCN
Nurse Manager, Cancer Center

Linda Christensen-Rengel, NP
Breast Health Center

Christine Colbach, MD
Pathology

Kevin Collis, RN, OCN
Nurse Navigator

Janel Cox, MD
Radiation Therapy

Kim Duffy, RD
Food and Nutritional Services

Holly Guida, RN-BSN, MBA
Oncology Operations Specialist

Laura Holasek
Director, Cancer Center

Amanda Horn, RN, OCN, BSN
Research Nurse

Randy Hurley, MD
Medical Oncology

Cindy Johnston
Genetic Counselor

Karen Lin, CTR
Cancer Registry

Rory Malloy
Quality Management

Pam Mason
American Cancer Society

Todd Morris, MD
General Surgery, Surgical Oncology

Gretchen Niemioja, MD
Rehabilitation Services

James Risser, MD
Internal Medicine, Palliative Care

Rob Ruff
Pastoral Care

James Schlaefer, MD
General Surgery, Surgical Oncology
(Cancer Liaison Fellow, American College of Surgeons)

Caitlyn Squire,
LICSW, OSW-C
Social Services

Bonnie Sweeney, RN
Nursing

Beth Werner, RN, MS,
CHPN, CHPCA
HealthPartners Hospice and Palliative Care

PARK NICOLLET

Christopher Chow, MD
Colon and Rectal Surgery

Britt Erickson, MD
Gynecology Oncology

Whitney Evavold, MD
Hospitalist

Kim Fenton, MBA
Oncology Program Manager

Jim Ferguson
Chaplain

Kelly Furda, MD
Radiologist

Nancy Gelle, BSN, RN
Palliative Care, Home Care, Hospice

Jennifer Grant
American Cancer Society

Howard Haines, MN
Emergency Medicine

Michael Haley, MD
Radiation Oncology

Kristin Hanrahan
Quality Improvement

Megan Hanson, MS, CGC
Genetics

Keith Heaton, MD
General Surgery, Surgical Oncology
(Cancer Liaison Fellow, American College of Surgeons)

Laura Holasek
Director, Cancer Center

Anne Hopkins, RN, OCN
Manager, Medical Oncology and Infusion

Susan Koering, Med, RHIA, CTR
Oncology Registry

Christian Loger
Jane Brattain Breast Center

Laura Maybon, RN
Oncology Research

Matt McCoy, MD
Pathology

Michael Miovic, MD
Psychosocial Services

Vicki Norton, BSN, OCN, RN
Nursing

Carol Ann Petersen,
LICSW, MAHS
Patient Support and Education

Jocelyn Rieder, MD
Urology

Bryan Schuler, PharmD, BCOP
Pharmacy

Paul Spilde, PT
Rehabilitation Services

Eric Weinberg, MD
Diagnostic Radiology

Mark Wilkowske, MD
Medical Oncology
In 2016, through Regions Hospital Foundation and Park Nicollet Foundation, 2,152 donors gave more than $4.3 million to support meaningful care for those affected by cancer at Regions Cancer Care Center and Park Nicollet Frauenshuh Cancer Center.

Park Nicollet Foundation

DONORS MAKE IT HAPPEN
In 2016, Park Nicollet Foundation’s Love & Legacy campaign reached our goal to support the expansion of Park Nicollet Frauenshuh Cancer Center and our Survivorship Program.

You play an important role in ensuring the sustainability of our programs, including:

- Cancer education
- Integrative therapies
- Non-moving patient care model
- Patient special needs
- Patient support groups
- Survivorship Program

BE A PART OF OUR MISSION IN ACTION
Contact Park Nicollet Foundation at 952-993-5023 or foundation@parknicollet.com

Regions Hospital Foundation

DONORS BRING HOPE TO CANCER PATIENTS
In 2016, Regions Hospital Foundation’s Wine Auction, presented by the Engdahl Family Foundation, raised funds to support the development of a new early-phase cancer research program.

Your generous gifts to Regions Hospital Cancer Care Center support:

- Basic needs assistance
- Care navigation assistance
- Classes and support groups
- Clinical cancer research
- Music and massage therapy

FIND OUT HOW YOU CAN MAKE A DIFFERENCE
Contact Regions Hospital Foundation at 651-254-2376 or rhf@healthpartners.com

Give hope. Give possibility.
When you are diagnosed with cancer, it is a very powerless feeling. By designing the treatment rooms around the patient, where everything comes to you, Park Nicollet Frauenshuh Cancer Center gave me back a little bit of that power. I had the most active and important voice in the treatment process. It was tremendously healing.”

– Amy, three-time breast cancer survivor

Five years ago, my wife received treatment at Regions Hospital for a virulent form of colon cancer. The cancer was caught early, and her life was saved. Regions cares for everyone and it also has strong teaching and research components. This was key to my family’s appreciation of Regions, especially in regards to cancer treatments.”

– Brian Engdahl, cancer research donor

Share your gratitude

Are you looking for a way to honor or thank someone who has helped you in your journey with cancer? Our foundations can help you find an opportunity to say thank you to the health care team members who played a special role in your care.
HealthPartners Institute – advancing health and health care

HealthPartners Institute is a 501c3 non-profit organization with researchers dedicated to conducting high-quality, public-domain health research. The institute is an affiliate member of Cancer Research Network (CRN) and a participant in the National Cancer Institute-funded CRN IV program. HealthPartners research includes projects and initiatives of Park Nicollet. Pamala Pawloski, PharmD, is the site primary investigator and a CRN scholar, a role that allows her to be a mentor to new investigators. For more information, visit healthpartners.com/institute.

To make an appointment, please call:

Park Nicollet Frauenshuh Cancer Center at 952-993-3248

 Regions Hospital Cancer Care Center at 651-254-3572

HealthPartners Cancer Care Center — Riverside at 612-341-4800

Park Nicollet Clinic & Specialty Center — Burnsville at 952-993-3248

Park Nicollet Clinic & Specialty Center — Maple Grove at 952-993-3248

For more information or to make a referral, contact Laura Holasek at laura.holasek@parknicollet.com or 651-254-4656.